Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6

Scientific Reports

Volumn 3, Issue , 2013, Pages

  MacCallum, Stephanie F ^a   Groves, Michael J ^a   James, John ^a   Murray, Karen ^a   Appleyard, Virginia ^a   Prescott, Alan R ^a   Drbal, Abed A ^b   Nicolaou, Anna ^b   Cunningham, Joan ^c   Haydock, Sally ^c   Ganley, Ian G ^a   Westwood, Nicholas J ^d   Coates, Philip J ^a   Lain, Sonia ^a,e   Tauro, Sudhir ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d Fife   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; BENZAMIDE DERIVATIVE; LIGHT CHAIN 3, HUMAN; MACROLIDE; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN P53; SIRTUIN; TENOVIN 6; TENOVIN-6;

AGED; ANIMAL; ARTICLE; AUTOPHAGY; CANCER STEM CELL; CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; LYSOSOME; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY;

AGED; ANIMALS; AUTOPHAGY; BENZAMIDES; CELLS, CULTURED; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYSOSOMES; MACROLIDES; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASTIC STEM CELLS; SIRTUINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874339014     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01275     Document Type: Article

References (51)

1. Rosenwald, A. et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood. 104, 1428-1434 (2004).
2. Moussay, E. et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer. 9, 115 (2010).
3. Ferracin, M. et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 9, 123 (2010).
4. Pettitt, A. R. et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 98, 814-822 (2001).
5. Zenz, T. et al. TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with longterm follow-up. Blood. 112, 3322-3329 (2008).
6. Malcikova, J. et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 114, 5307-5314 (2009).
7. Zenz, T. et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 114, 2589-2597 (2009).
8. Hallek, M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 376, 1164-1174 (2010).
9. Inoue, S., Mai, A., Dyer, M. J. & Cohen, G. M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66, 6785-6792 (2006).
10. Ellis, L., Atadja, P. W. & Johnstone, R. W. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 8, 1409-1420 (2009).
11. Lane, A. A. & Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 27, 5459-5468 (2009).
12. Bots, M. & Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin Cancer Res. 15, 3970-3977 (2009).
13. Stamatopoulos, B. et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia. 23, 2281-2289 (2009).
14. El-Khoury, V. et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther. 9, 1349-1360 (2010).
15. Audrito, V. et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activationofthe p53/miR-34a/SIRT1 Tumor Suppressor Network. Cancer Res. 71, 4473-4483 (2011).
16. Cea, M. et al. Synergistic interactions between HDAC and Sirtuin inhibitors in human leukemia Cells. PloS One. 6, e22739. (2011).
17. Dali-Youcef, N. et al. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med. 39, 335-345 (2007).
18. Guarantee, L. & Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med. 364, 2235-2244 (2011).
19. Madeo, F., Tavernarakis, N. & Kroemer, G. Can autophagy promote longevity? Nat Cell Biol. 12, 842-846 (2010).
20. Morselli, E. et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis. 1, e10 (2010).
21. Luo, J. et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107, 137-148 (2001).
22. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependentp53 deacetylase. Cell. 107, 149-159 (2001).
23. McCarthy, A. R. et al. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg Med Chem. 20, 1779-1793 (2012).
24. Lain, S. et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 13, 454-463 (2008).
25. McCarthy, A. R., Hollick, J. J. & Westwood, N. J. The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screen. Semin Cancer Biol. 20, 40-45 (2010).
26. Li, L. et al. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell. 21, 266-281 (2012).
27. Yuan, H. et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119, 1904-1914 (2012).
28. Sanders, B. D., Jackson, B. & Marmorstein, R. Structural basis for sirtuin function: whatwe know and whatwe don't. Biochim Biophys Acta. 1804, 1604-1616 (2010).
29. Orchard, J. A. et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 363, 105-111 (2004).
30. Li, C. & Wong, W. H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 98, 31-36 (2001).
31. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20, 307-315 (2004).
32. Tumor Analysis Best Practices Working Group. Expression profiling-best practices for data generation and interpretation in clinical trials. Nat Rev Genet. 5, 29-37 (2004).
33. Reynolds, E. S. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol. 17, 208-212 (1963).
34. Wang, J. C. et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology. 81, 325-329 (2011).
35. Van Damme, M. et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics. Oct 29, 7, (2012) [Epub ahead of print].
36. Jegga, A. G., Schneider, L., Ouyang, X. & Zhang, J. Systems biology of the autophagy-lysosomal pathway. Autophagy. 7, 477-489 (2011).
37. Taatjes, D. J., Sobel, B. E. & Budd, R. C. Morphological and cytochemical determination of cell death by apoptosis. Histochem Cell Biol. 129, 33-43 (2008).
38. Eskelinen, E. L., Reggiori, F., Baba, M., Kovács, A. L. & Seglen, P. O. Seeing is believing: the impact of electron microscopy on autophagy research. Autophagy. 7, 935-956 (2011).
39. Barth, S., Glick, D. & Macleod, K. F. Autophagy: assays and artifacts. J Pathol. 221, 117-1124 (2010).
40. Glick, D., Barth, S. & Macleod, K. F. Autophagy: cellular and molecular mechanisms. J Pathol. 221, 3-12 (2010).
41. Garćia-Mart́inez, J. M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J. 421, 29-42 (2009).
42. Bjørkøy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 171, 603-614 (2005).
43. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 8, 445-544 (2012).
44. Kim, R. et al. Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol. 208, 319-26 (2006).
45. Pettitt, A. R., Sherrington, P. D. & Cawley, J. C. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues. Cancer Res. 60, 4187-4193 (2000).
46. Marshall, G. M. et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects ofMKP3 and ERK on N-Myc protein stability. PLoS Genet. 7, e1002135 (2011).
47. Wang, B. et al. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 30, 907-921 (2011).
48. Walker, A. K. et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24, 1403-1417 (2010).
49. Houtkooper, R. H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 13, 225-238 (2012).
50. Mahoney, E. et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 120, 1262-1273 (2012).
51. Kovaleva, V. et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res. 72, 1763-1772 (2012).